Related Experiment Videos
Mivacurium in special patient groups
1St Mary's Hospital Medical School, London, UK.
Insights
Mivacurium dosing varies significantly in special patient populations, including children, the elderly, and those with renal or hepatic impairment. Careful monitoring ensures safe use of this neuromuscular blocking agent in diverse patient groups.
Area of Science:
- Pharmacology
- Anesthesiology
- Clinical Pharmacy
Background:
- Drug response can differ in special patient groups compared to healthy adults.
- Mivacurium is a neuromuscular blocking agent whose dosage may be affected by patient-specific factors.
Purpose of the Study:
- To review the variable dose requirements of mivacurium in special patient groups.
- To highlight the importance of monitoring drug effect in these populations.
Main Methods:
- Review of existing literature on mivacurium pharmacokinetics and pharmacodynamics.
- Analysis of factors influencing mivacurium dose requirements, including age, renal function, and hepatic function.
Main Results:
- Children generally require larger mivacurium doses, while the elderly often need smaller doses.
- Neonatal dose requirements may not significantly differ from adults.
- Reduced plasma cholinesterase activity in patients with renal or severe liver disease necessitates smaller mivacurium doses.
Conclusions:
- Mivacurium dosage must be adjusted based on patient age, renal, and hepatic status.
- Appropriate monitoring of the neuromuscular block is crucial for safe mivacurium administration in special populations.
- With careful consideration of dose variations, mivacurium can be safely used in pediatric, elderly, and renally or hepatically impaired patients.
Abstract:
In special patient groups, drug response may be different from that in the healthy adult patient. Mivacurium dose requirements vary with age, and children require larger doses to obtain any given degree of block, but the elderly often require smaller doses. However, the dose requirements of the neonate do not necessarily differ greatly from those of the adult. There is a relationship between the duration of action of a bolus dose as well as infusion requirements to maintain block and the plasma cholinesterase activity. Patients with renal disease may have a decreased cholinesterase activity and may require smaller doses of mivacurium. Patients with severe liver disease may have a marked decrease in cholinesterase activity, and in these patients a substantially smaller dose of the drug may be needed to obtain and maintain any given degree of block. If the variation in dose requirements is kept in mind and the degree of block appropriately monitored, mivacurium may be used with safety in special patient groups, such as children, the elderly, or those with renal or hepatic impairment.